Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers

doi:10.3390/books978-3-0365-2686-7

Download Url(s)

https://mdpi.com/books/pdfview/book/4898

Contributor(s)

Kayser, Veysel (editor)

Language

English

Show full item record

Abstract

The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody–Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment.

URI

https://directory.doabooks.org/handle/20.500.12854/78803

Keywords

monoclonal antibody; NSCLC; immunotherapy; ELISA; pharmacokinetics; pharmacogenetics; anti-PD-1 monoclonal antibodies; anti-acetylcholine receptor (AChR) antibody; B cell; immune checkpoint blockade; immune-related adverse events (irAEs); myasthenia gravis (MG); non-small-cell lung cancer (NSCLC); nivolumab; programmed cell death ligand 1 (PD-L1); T cell; tetraspanins; cancer; Tspan8; radioimmunotherapy; immune-checkpoint inhibitors; LDH; biomarkers; Ang-2; antiangiogenic therapy; in vivo imaging; radio- and chemotherapy; VEGF-A; cancer therapy; neovascularization; angiogenesis; tumor microenvironment; colorectal cancer; antibody; NK cells; ADCC; CD133; prominin-1; gold nanoparticles; antibody-drug conjugates; cell penetrating peptide; HIV-1 TAT; active-targeting; targeted delivery; trastuzumab; MMAE; valine-citrulline; affibody; drug conjugates; hepatic uptake; DM1; dermatooncology; immune checkpoints; monoclonal antibodies; passive immunotherapy; canine B-cell lymphoma; DLA-DR; HLA-DR; antibody-drug conjugate; ADC; methotrexate; tumor immunity; combination therapy; multiple myeloma (MM); monoclonal antibodies (mAbs); antibody products; B cell maturation antigens (BCMAs); bispecific T cell engagers (BiTEs®); checkpoint inhibitors 1; protein structure 2; pharmacokinetics 3; drug optimization 4; HER2-positive breast cancer; metastatic disease; neoadjuvant and adjuvant therapy; targeted therapy; acute myeloid leukemia; CD123; IL3RA; kinesin spindle protein inhibitor